Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017034420) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/034420 International Application No.: PCT/NZ2016/050135
Publication Date: 02.03.2017 International Filing Date: 25.08.2016
IPC:
C07D 498/04 (2006.01) ,A61K 31/437 (2006.01) ,A61P 9/04 (2006.01) ,A61P 13/12 (2006.01) ,A61P 15/00 (2006.01) ,A61P 25/00 (2006.01) ,A61P 27/12 (2006.01) ,A61P 29/00 (2006.01) ,A61P 31/00 (2006.01) ,A61P 35/00 (2006.01)
[IPC code unknown for C07D 498/04][IPC code unknown for A61K 31/437][IPC code unknown for A61P 9/04][IPC code unknown for A61P 13/12][IPC code unknown for A61P 15][IPC code unknown for A61P 25][IPC code unknown for A61P 27/12][IPC code unknown for A61P 29][IPC code unknown for A61P 31][IPC code unknown for A61P 35]
Applicants:
AUCKLAND UNISERVICES LIMITED [NZ/NZ]; Level 10 70 Symonds Street Auckland, NZ
Inventors:
PALMER, Brian Desmond; NZ
CHING, Lai-Ming; NZ
Agent:
AJ PARK; Level 22, State Insurance Tower 1 Willis Street Wellington, NZ
Priority Data:
71151427.08.2015NZ
Title (EN) INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY
(FR) INHIBITEURS DES TRYPTOPHANE-DIOXYGÉNASES (IDO1 ET TDO) ET LEUR UTILISATION EN THÉRAPIE
Abstract:
(EN) Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
(FR) L'invention concerne des compositions pharmaceutiques comprenant des composés 3-amino-isoxazolopyridines de formule I ayant une activité inhibitrice d'IDO1 et/ou de TDO, dans laquelle W représente CR1, N ou N-oxyde; X représente CR2, N ou N-oxyde; Y représente CR3, N ou N-oxyde; Z représente CR4, N ou N-oxyde; et W, X, Y et/ou Z représentent N ou N-oxyde; et R9 et R10 sont tels que définis. L'invention concerne également des méthodes d'utilisation de tels composés dans le traitement de diverses affections, telles que le cancer.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)